Thymectacin

Thymectacin (NB1011) is an agent selectively targeting tumor cells that have a high expression of thymidylate synthase (TS) . Thymectacin is an aryloxy phosphoramidate derivative of BVdU (brivudin) [1][2].

Product Specifications

CAS Number

[232925-18-7]

Product Name Alternative

NB1011

UNSPSC

12352005

Target

Thymidylate Synthase

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/thymectacin.html

Purity

98.21

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O[C@H]1C[C@H](N2C=C(/C=C/Br)C(NC2=O)=O)O[C@@H]1COP(N[C@@H](C)C(OC)=O)(OC3=CC=CC=C3)=O

Molecular Formula

C21H25BrN3O9P

Molecular Weight

574.32

References & Citations

[1]Wilson RH. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. Oncologist. 2006;11 (9) :1018-1024.|[2] Congiatu C, et al. Novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center. J Med Chem. 2006;49 (2) :452-455.